Source: Supply Chain Brain
Date: 24th February 2025

Rising geopolitical tensions, pandemic disruptions, and supply chain vulnerabilities prompt a push to reshore or nearshore pharmaceutical manufacturing.

The pharmaceutical industry in the United States is re-evaluating its long-standing dependence on offshore drug production. Triggered by the COVID-19 pandemic and growing geopolitical instability, there’s a renewed focus on sourcing pharmaceuticals closer to home—either within the U.S. or from neighbouring countries such as Mexico.

Over the past two decades, the share of domestically produced drugs has steadily declined, increasing the risk of supply disruptions. In response, both public and private sectors are beginning to invest in strengthening domestic production capabilities.

Smaller pharmaceutical companies and startups are leading the shift back to U.S.-based manufacturing, motivated by greater supply chain control, rising overseas production costs, and consumer appeal for “Made in USA” products.

However, larger corporations remain heavily reliant on cost-effective offshore sites like China, India, and Ireland, especially for the production of generics and biosimilars. These offshore facilities offer competitive advantages in labour and capital expenditures, keeping them attractive despite growing risks.

Still, significant challenges stand in the way of a broader reshoring movement. High domestic labour costs, stringent regulatory requirements, and ongoing dependence on foreign raw materials all add complexity.

For large-scale reshoring to succeed, changes in tax policy and infrastructure support may be required. While reshoring could enhance supply chain resilience, it may also lead to increased drug prices, potentially impacting competitiveness in the global market.

The industry now faces a pivotal moment—balancing cost efficiency with long-term stability and strategic independence.